

The Gimema Infection Program is a national cooperative group devoted to the anti-infective supportive care in onco-hematological patients undergoing chemotherapy or receiving HSCT.

The group is affiliate to the GIMEMA, a well known cooperative group in the field of the hematology.

The Gimema Infection Program started their research at the end of the 80' performing clinical trials in the field of febrile neutropenia.

Several trials were done on:

1. antibacterial prophylaxis (ciprofloxacin vs. norfloxaci; levofloxacin vs. placebo)
2. antifungal prophylaxis (fluconazole vs. amphotericin B; itraconazole vs. placebo)
3. empiric antibiotic therapy of febrile neutropenia (teicoplanin, vs. vancomycin; meropenem; piperacillin/tazobactam).
4. The results of these trials wer published on the most important international journals (see attached list).

A part from the clinical research activity, the group promoted an intense and persistent educational program to promote knowledge and appropriateness in the diagnosis and management of infections in cancer patients.

The Gimema Infection Program has recently cooperate ith some of their experts (Dr. Francesco Menichetti, one of the coordinators togheter with Prof. Albano Del Favero, Perugia and Piero Martino, Rome) to the preparation of the European Guidelines for the Treatment of Infections in Acute Leukemia Patients promoted by several european collaborative groups (EORTC, EBMT, etc.)